Stop Stigma Now Inc

Nonprofit profile at a glance

EIN
473761586
IRS 990-EZ coverage
2021–2025
Forms available
Form 990-EZ 2025
Location
New Rochelle, NY, USA
Phone
9143184442
Rating
74
Verdict
SUPPORTED
Rating confidence
Moderate
Sector
Alliance/Advocacy Organizations

Official website

Reported finances

Revenue
$55,678
Expenses
$14,862
Assets
$113,123
Liabilities
$80

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Amounts in USD.

Leadership & pay

12 people listed

Executive titles in this filing

  • JOHN PHILLIPS (PRESIDENT)
  • VALERIE WALTERS (VICE PRESIDENT)
  • SUSAN STAATS COMBS (VICE PRESIDENT)

People named in this filing

  • JOHN PHILLIPS (PRESIDENT)
  • VALERIE WALTERS (VICE PRESIDENT)
  • SUSAN STAATS COMBS (VICE PRESIDENT)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990-EZ. Selected filing: tax year 2025. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

Stop stigma now was established to change prevailing attitudes towards people suffering from substance use disorders, which are preventing them from entering into and remaining in treatment.

What it reported doing in 2025

Stop stigma now (ssn), consisting of active and retired professionals, and patients, is a think tank that delivers trusted insight on the benefits of medication treatment for opioid use disorder (moud) and educates the wider public on the stigma associated with moud.our agenda is simple: to help stop the stigma and prejudice directed at both the treatment and the patients.stop stigma now was established to change prevailing attitudes towards people suffering from opioid use disorder (oud), which are preventing them from entering into and remaining in treatment.while many treatments for oud exist, (i.e., medication treatment, in-patient rehabilitation, therapeutic communities, outpatient counseling,) the use of medications (methadone, buprenorphine and extended-release naltrexone) has repeatedly been documented to be the most effective. Compared to other treatments, patients maintained on medication are less likely to relapse, acquire infectious diseases such as HIV and hepatitis c, and die from an opioid overdose. Unfortunately, these medications especially the agonist medications (methadone and buprenorphine) have been misunderstood and criticized as substituting one addiction for another. Agonist medications for oud block the craving for opioids and suppress opioid withdrawal thus enabling the return to full functioning and a normal life.because oud patients may have other problems such as a history of trauma, other addictive disorders, chronic pain and other psycho-social problems, medication treatment often includes counseling and other support services as needed or indicated.all treatments should be respected. However, for persons with oud, non-medication approaches to treatment that do not include moud, whether it be abstinence, or detox, or in or out-patient treatment, fall short of the effectiveness of moud, thus may put individuals in a dangerous situation which can result in relapse, overdose and death.ssn exists to inform the general public, the court system, public officials, medical, nursing and counseling professions and the media about the overwhelming scientific evidence supporting the success of medication treatment for opioid use disorder.by eradicating stigma, we save and rebuild lives. It's as simple as that! Ssn creates, designs, develops and distributes educational materials (books, pamphlets, posters, ads, cards and buttons, etc.) to help organizations effectively respond to concerns voiced by public officials, medical professionals, the media, the courts and the community at large.all materials and services are free at ssn

Operating model

Revenue model
Donor-supported. 100% of the money available for current operations came from contributions and gifts.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

SUPPORTED - The filed numbers largely add up and revenue comfortably covers expenses. A relatively small share of available resources goes toward mission work and program spending has declined or grown slowly.

Rating breakdown

  • Financial Efficiency: 54
  • Transparency & Controls: 100
  • Sustainability: 82
  • Growth: 60

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 26.7%; rating input score 27
  • Program expense ratio: 100%; rating input score 100

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 51st percentile among comparable filings
  • Major donor itemization: Yes; rating input score 100

Sustainability

  • Operating margin: 73.3%; rating input score 96; 96th percentile among comparable filings
  • Total-asset coverage ratio: 7.61; rating input score 89; 89th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 31; 31st percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 56; 56th percentile among comparable filings

Growth

  • Program expense growth: -10.7% per year; rating input score 0; 27th percentile among comparable filings
  • Revenue growth: 5.8% per year; rating input score 100; 72nd percentile among comparable filings
  • Asset growth: 25.4% per year; rating input score 100; 88th percentile among comparable filings

Details

  • Where the money goes: 26.7% of revenue deployed · 100% of spending went to programs
  • Governance: Filed governance answers
  • Accomplishments: 1 filed program accomplishment · $15K in reported program spending
  • Leadership: top reported pay $0 · 12 people listed
  • Consistency: 8 of 8 current checks pass
  • Schedules: 3 filed schedules
  • Filing history: 5 filing years from 2021 to 2025
  • Contacts: How to reach this organization
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • High — Financial Efficiency: Mission deployment rate scored 27/100.
  • High — Growth: Program expense growth scored 0/100.
  • Moderate — Sustainability: Liabilities to assets ratio scored 31/100.
  • Review — Sustainability: Officer compensation ratio scored 56/100.